E2F1 and glioma: While the position of E2F1 as a prognosis marker of glioma is debated [52, 53], abnormalities of the p16/pRb/E2F pathway with over-expression of E2F are present in most of gliomas and suggest E2F1 as a potential therapeutic target [54].